- Home
- ABVC vs CALC Comparison
ABVC vs CALC Comparison
Compare ABVC & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- CALC
- Stock Information
- Founded
- ABVC 2015
- CALC 2011
- Country
- ABVC United States
- CALC United States
- Employees
- ABVC N/A
- CALC N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- CALC Health Care
- Exchange
- ABVC Nasdaq
- CALC Nasdaq
- Market Cap
- ABVC 52.1M
- CALC 48.1M
- IPO Year
- ABVC N/A
- CALC N/A
- Fundamental
- Price
- ABVC $2.72
- CALC $3.21
- Analyst Decision
- ABVC
- CALC Strong Buy
- Analyst Count
- ABVC 0
- CALC 2
- Target Price
- ABVC N/A
- CALC $14.50
- AVG Volume (30 Days)
- ABVC 82.8K
- CALC 75.5K
- Earning Date
- ABVC 11-13-2025
- CALC 11-12-2025
- Dividend Yield
- ABVC N/A
- CALC N/A
- EPS Growth
- ABVC N/A
- CALC N/A
- EPS
- ABVC N/A
- CALC N/A
- Revenue
- ABVC $391,242.00
- CALC N/A
- Revenue This Year
- ABVC $735.18
- CALC N/A
- Revenue Next Year
- ABVC N/A
- CALC N/A
- P/E Ratio
- ABVC N/A
- CALC N/A
- Revenue Growth
- ABVC 186.84
- CALC N/A
- 52 Week Low
- ABVC $0.40
- CALC $1.42
- 52 Week High
- ABVC $5.48
- CALC $5.65
- Technical
- Relative Strength Index (RSI)
- ABVC 45.18
- CALC 54.27
- Support Level
- ABVC $2.64
- CALC $2.62
- Resistance Level
- ABVC $2.90
- CALC $3.31
- Average True Range (ATR)
- ABVC 0.16
- CALC 0.35
- MACD
- ABVC 0.00
- CALC -0.01
- Stochastic Oscillator
- ABVC 33.87
- CALC 53.15
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.